REG - Ondine Biomedical - Update on Private Placement and Placing

Ondine BiomedicalAnnouncement

11/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241111:nRSK6846La&default-theme=true

RNS Number : 6846L  Ondine Biomedical Inc.  11 November 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

 

Update on Private Placement and Placing

 

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company,
announces an update to its Private Placement announced on 24 September 2024
and the Fundraising announced on 1 November 2024.

 

The settlement of the Private Placement with a Canadian private investor has
been delayed due to their unavoidable personal circumstances and will require
additional time to complete. In light of this, settlement of the Fundraising
scheduled for Nov 11 will also be delayed coinciding with the Private
Placement settlement. Further updates will be provided in due course.

 

-Ends-

 

Enquiries:

 

 Ondine Biomedical Inc.
 Angelika Vance, Vice President of Corporate Communications      +001 604 838 2702

 Singer Capital Markets (Nominated Adviser, Joint Broker)
 Phil Davies, Sam Butcher                                        +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                                  +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact for Ondine Biomedial)      +44 (0)77 1000 5910
 Simon Vane Percy, Amanda Bernard

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader
innovating light-activated antimicrobial therapies (also known as
'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name
Steriwave(®). In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDKZMMMVMKGDZG